Current Partners

Amunix believes in the power of partnerships and collaborative efforts, and has a long history of joint research and development projects. Together with our partners, we have advanced the development of novel therapeutics to treat cancer, gastrointestinal diseases, hormone deficiencies, blood disorders, and more.

Our established agreements and partnerships include:

  • Janssen
  • Biogen-Idec
  • Noxxon
  • Zealand
  • Baxalta
  • Ambrx
  • Seattle Genetics
  • Versartis

2014

Amunix signed an expansion of an ongoing collaboration agreement with Janssen Biotech, Inc. to apply XTEN™ to an undisclosed target and the number of available options for potential products was increased.

Amunix Signed a Services and Supply Agreement with the University of Nebraska-Lincoln to produce GMP-Grade XTEN for Pharmaceutical Therapeutics.  For more information, see the press release.

2013

Amunix signed a collaboration agreement with Janssen Biotech, Inc. in the engineering of up to three XTEN fusion proteins.

An additional product was exercised under Amunix’s worldwide research collaboration and licensing agreement with Janssen Biotech, Inc.

2012

Amunix signed a collaboration agreement with a large U.S. pharma company to apply XTEN to an undisclosed target.

Amunix signed an expansion of an ongoing collaboration agreement with a top-10 large pharma company to apply XTEN to an undisclosed target.

Amunix signed a collaboration agreement with a top-10 large pharma company to apply XTEN to undisclosed targets.

Amunix signed a collaboration agreement with Shire to apply XTEN to an undisclosed target.

2011

Amunix has entered into a research collaboration with Biogen Idec on XTEN–derivatives of blood factors (FVIIa, FVIII and FIX) with improved therapeutic properties.  For more information, see the press release.

Amunix signed a collaboration agreement with a top-10 large pharma company to apply XTEN to an undisclosed target.

Amunix signed a collaboration agreement with a top-5 large pharma company to apply XTEN to an undisclosed target.

2010

Diartis is a clinical development spin-out from Amunix that has recently completed a Phase I clinical trial of Exenatide-XTEN.

2009

Versartis is a clinical development spin-out from Amunix that has recently completed a Phase I clinical trial of growth hormone-XTEN. For more information, see www.versartis.com.

2007

Amunix signed a three-year collaboration agreement with Pfizer.  Pfizer selected multiple compounds that are undergoing further development.

List of Alliances

versartis-inc-logo

Versartis has completed a phase 2a clinical trial in pre-pubertal children with VRS-317 – a long acting human growth hormone that utilizes Amunix’s XTEN™ half-life technology.

tit-janssen

Amunix has formed partnerships with Janssen, Biotech Inc. to develop products in a wide range of therapeutic areas and is collaborating with Biogen Idec to develop new, long-acting blood factors for the treatment of hemophilia.

Additional collaborations with a number of other large pharmaceutical companies to apply XTEN™ to undisclosed targets are also ongoing.